By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK


Company News
FDA Approves Eisai Inc. (ESALF.PK)'s Halaven (eribulin mesylate) Injection For The Treatment Of Patients With Advanced Liposarcoma 1/29/2016 6:17:48 AM
Halozyme (HALO) And Eisai Inc. (ESALF.PK) To Present Data Evaluating The Antitumor Effects Of PEGPH20 In Combination With Eribulin Mesylate In Preclinical Breast Cancer Models 12/9/2015 7:48:32 AM
Eisai Inc. (ESALF.PK) Divests Clinical Diagnostics Supply Biz for $183 Million 11/30/2015 8:24:05 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce FDA Acceptance Of New Drug Application For Extended Release Formulation Of Lorcaserin 11/30/2015 6:50:11 AM
Eisai Inc. (ESALF.PK) Release: Results From Phase 2 Trial Investigating Lenvatinib In Metastatic Renal Cell Carcinoma Published In The Lancet Oncology 10/16/2015 8:03:22 AM
FDA Grants Eisai Inc. (ESALF.PK)'s sNDA For Eribulin Priority Review Designation For The Potential Treatment Of Advanced Soft Tissue Sarcoma 9/28/2015 6:24:37 AM
Eisai Inc. (ESALF.PK) Expands Magnolia Meals At Home Program To Help People Living With Thyroid Cancer 9/25/2015 10:48:13 AM
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Presentation Of Lorcaserin HCl Data At Upcoming Medical Meetings 9/25/2015 10:26:53 AM
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Sign Collaboration Agreement To Investigate Eribulin And PEGPH20 In Metastatic Breast Cancer 7/31/2015 11:06:32 AM
Eisai Inc. (ESALF.PK) Submits Simultaneous Regulatory Applications For Eribulin In Soft Tissue Sarcoma In The United States, European Union And Japan 7/30/2015 12:05:38 PM